GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance

Clinical trials revealed limited response duration of glioblastomas to VEGF-neutralizing antibody bevacizumab. Thriving in the devascularized microenvironment occurring after antiangiogenic therapy requires tumor cell adaptation to decreased glucose, with 50% less glucose identified in bevacizumab-t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JCI Insight
Autores principales: Kuang, Ruby, Jahangiri, Arman, Mascharak, Smita, Nguyen, Alan, Chandra, Ankush, Flanigan, Patrick M., Yagnik, Garima, Wagner, Jeffrey R., De Lay, Michael, Carrera, Diego, Castro, Brandyn A., Hayes, Josie, Sidorov, Maxim, Garcia, Jose Luiz Izquierdo, Eriksson, Pia, Ronen, Sabrina, Phillips, Joanna, Molinaro, Annette, Koliwad, Suneil, Aghi, Manish K.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Clinical Investigation 2017
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5256137/
https://ncbi.nlm.nih.gov/pubmed/28138554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.88815
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares